Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI)

Renaissance Technologies LLC lifted its holdings in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 10.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,800 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned about 0.30% of CASI Pharmaceuticals worth $224,000 at the end of the most recent quarter.

Separately, Howland Capital Management LLC acquired a new position in shares of CASI Pharmaceuticals during the 1st quarter worth about $146,000. Institutional investors and hedge funds own 22.23% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on CASI Pharmaceuticals in a research report on Saturday, August 3rd. They set a “hold” rating for the company.

CASI Pharmaceuticals Trading Down 1.0 %

NASDAQ:CASI opened at $5.82 on Friday. CASI Pharmaceuticals, Inc. has a twelve month low of $2.05 and a twelve month high of $8.48. The company has a quick ratio of 2.36, a current ratio of 3.88 and a debt-to-equity ratio of 2.05. The business has a 50 day moving average price of $6.35 and a two-hundred day moving average price of $4.81. The company has a market cap of $77.99 million, a P/E ratio of -2.55 and a beta of 0.69.

CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings results on Friday, August 16th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. CASI Pharmaceuticals had a negative return on equity of 126.20% and a negative net margin of 118.81%. The firm had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.43 million.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.